Stocks › CRSP

CRISPR Therapeutics AG

CRSP·Nasdaq·USD
$39.10
+0.17 (+0.44%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CRSP
CRISPR Therapeutics AG · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CRSPS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of CRSP by members of U.S. Congress · 7 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Thomas R. SuozziThomas R. SuozziHouse · D · NY CRSPCRISPR Therapeutics AG · Stock Sale
$50,001 - $100,000
Oct 5, 2021 Sep 20, 2021 Filing ↗
Thomas R. SuozziThomas R. SuozziHouse · D · NY CRSPCRISPR Therapeutics AG · Stock Purchase
$50,001 - $100,000
Sep 23, 2021 Jun 3, 2021 Filing ↗
Marjorie Taylor GreeneMarjorie Taylor GreeneHouse · R · GA CRSPCRISPR Therapeutics AG · Stock Purchase
$1,001 - $15,000
Feb 19, 2021 Jan 21, 2021 Filing ↗
James M InhofeJames M InhofeSenate · R · OK CRSPCRISPR Therapeutics AG · Stock Sale
$1,001 - $15,000
Jan 15, 2021 Jan 5, 2021 Filing ↗
James M InhofeJames M InhofeSenate · R · OK CRSPCRISPR Therapeutics AG · Stock Sale
$50,001 - $100,000
Dec 23, 2020 Dec 22, 2020 Filing ↗
James M InhofeJames M InhofeSenate · R · OK CRSPCRISPR Therapeutics AG · Stock Sale
$15,001 - $50,000
Jun 20, 2018 Jun 19, 2018 Filing ↗
James M InhofeJames M InhofeSenate · R · OK CRSPCRISPR Therapeutics AG · Stock Purchase
$15,001 - $50,000
Nov 8, 2017 Oct 19, 2017 Filing ↗

Whale Activity

Position changes in CRSP reported for 2026-09-30 by 567 institutional filers
Increased: 170New: 52Held: 124Decreased: 131Closed: 63No prior filing: 27
  • Increased170
  • New52
  • Held124
  • Decreased131
  • Closed63
  • No prior filing27
FilerSharesValueChange
ARK Investment Management LLC10.1M$556.3Mincreased
BlackRock, Inc.8.3M$459.1Mdecreased
STATE STREET CORP5.0M$276.3Mincreased
Capital World Investors4.7M$262.2Mdecreased
Orbis Allan Gray Ltd4.5M$250.0Mdecreased
GSK plc2.6M$144.3Mdecreased
GEODE CAPITAL MANAGEMENT, LLC2.5M$139.0Mincreased
SR ONE CAPITAL MANAGEMENT, LP2.0M$112.8Mheld
TWO SIGMA INVESTMENTS, LP2.0M$111.5Mincreased
FMR LLC1.9M$104.9Mdecreased
BANK OF AMERICA CORP /DE/1.7M$96.2Mincreased
T. Rowe Price Investment Management, Inc.1.7M$91.7Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by CRSP insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: -82.5K2025 Q12025 Q2: -2,4242025 Q22025 Q3: 996.7K2025 Q32025 Q4: -66.2K2025 Q42026 Q1: -220.1K2026 Q12026 Q2: -3,7862026 Q22026 Q3: -24.1K2026 Q32026 Q4: -69.5K2026 Q4

Recent Insider Transactions

987 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Kulkarni SamarthChief Executive Officer · Director Sale −47.8K $49.78 $2.4M Oct 19, 2026 Form 4 ↗
George SimeonDirector · Director Sale −14.5K $49.63 $720K Oct 14, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Sale −1,040 $49.26 $51K Oct 14, 2026 Form 4 ↗
Kulkarni SamarthChief Executive Officer · Director Sale −4,098 $49.26 $202K Oct 14, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Sale −1,990 $60.04 $119K Oct 6, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Sale −10.4K $60.24 $626K Sep 22, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Option exercise +10.4K $13.62 $142K Sep 22, 2026 Form 4 ↗
Behbahani AliDirector Sale −13.7K $57.09 $781K Sep 17, 2026 Form 4 ↗
Behbahani AliDirector Option exercise +30.0K $14.00 $420K Sep 17, 2026 Form 4 ↗
Prasad RajuChief Financial Officer Gift −750 $0.00 $0 Aug 7, 2026 Form 4 ↗
Patel NaimishChief Medical Officer Sale −3,786 $55.62 $211K May 29, 2026 Form 4 ↗
Patel NaimishChief Medical Officer Option exercise +10.0K — — May 28, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Sale −3,182 $46.78 $149K Mar 23, 2026 Form 4 ↗
Kulkarni SamarthChief Executive Officer · Director Sale −10.0K $46.78 $469K Mar 23, 2026 Form 4 ↗
Prasad RajuChief Financial Officer Sale −3,708 $46.78 $173K Mar 23, 2026 Form 4 ↗
KASINGER JAMES R.General Counsel and Secretary Option exercise +6,250 — — Mar 20, 2026 Form 4 ↗
Kulkarni SamarthChief Executive Officer · Director Option exercise +19.7K — — Mar 20, 2026 Form 4 ↗
Prasad RajuChief Financial Officer Option exercise +6,250 — — Mar 20, 2026 Form 4 ↗
Patel NaimishChief Medical Officer Sale −3,150 $48.26 $152K Mar 16, 2026 Form 4 ↗
Prasad RajuChief Financial Officer Gift −750 $0.00 $0 Mar 16, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding CRSP · SEC Form N-PORT
FundSharesValue% of fundAs of
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.1M$60.4M0.06%Jun 30, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
534.2K$30.4M0.17%Aug 31, 2026
Avantis U.S. Small Cap Equity ETF
American Century ETF Trust
151.4K$8.6M0.28%Aug 31, 2026
Nuveen Small Cap Blend Index Fund
TIAA-CREF Funds
121.6K$5.8M0.14%Jul 31, 2026
Empower T. Rowe Price Mid Cap Growth Fund
EMPOWER FUNDS, INC.
87.3K$4.8M0.25%Sep 30, 2026
VANGUARD RUSSELL 2000 VALUE INDEX FUND
VANGUARD SCOTTSDALE FUNDS
75.9K$4.3M0.30%Aug 31, 2026
VANGUARD TOTAL WORLD STOCK INDEX FUND
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS
75.4K$3.6M0.00%Jul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares
Direxion Shares ETF Trust
68.3K$3.3M0.66%Jul 31, 2026
Nuveen Equity Index Fund
TIAA-CREF Funds
67.2K$3.2M0.01%Jul 31, 2026
iShares Genomics Immunology and Healthcare ETF
iShares Trust
62.2K$3.0M1.57%Jul 31, 2026

Mutual funds and ETFs whose N-PORT filings list CRSP's shares (CUSIP H17182108), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 17.5K shares0.0%
    Nov 16, 2026 · ↗
  • ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 4.5M shares4.7%
    Nov 16, 2026 · ↗
  • Catherine D. WoodSCHEDULE 13G/A · passive (13G) · 10.1M shares10.4%
    Nov 13, 2026 · ↗
  • ARK Investment Management LLCSCHEDULE 13G/A · passive (13G) · 10.1M shares10.4%
    Nov 13, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 5.0M shares5.2%
    Nov 10, 2026 · ↗
  • Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
    Aug 14, 2026 · ↗
  • ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 5.4M shares5.6%
    Aug 14, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 8.0M shares8.3%
    Jul 27, 2026 · ↗
  • Allan Gray Australia Pty LtdSCHEDULE 13G/A · passive (13G) · 15.8K shares0.0%
    May 15, 2026 · ↗
  • ORBIS INVESTMENT MANAGEMENT LTDSCHEDULE 13G/A · passive (13G) · 6.1M shares6.3%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming crispr therapeutics ag as client

No lobbying filings found naming CRISPR Therapeutics AG as the client.

  • MMR, LLCCRISPR THERAPEUTICS AG · 2019 Q2—
    Filing ↗
  • MMR, LLCCRISPR THERAPEUTICS AG · 2019 Q2 · MED—
    Filing ↗

Government Contracts

Federal awards to CRISPR Therapeutics AG · USAspending

No federal contract awards found for CRISPR Therapeutics AG.

U.S. Patents

Recent USPTO applications naming CRISPR Therapeutics AG

No USPTO patent applications found for CRISPR Therapeutics AG.

Annual Financials

From CRSP's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$3.5M$37.3M$371.2M$1.2M$915.0M
Operating income-$664.6M-$466.6M-$222.5M-$673.2M$373.5M
Net income-$581.6M-$366.3M-$153.6M-$650.2M$377.7M
Diluted EPS-$6.47-$4.34-$1.94-$8.36$4.70
Operating cash flow-$345.0M-$142.8M-$260.4M-$495.7M$539.0M
Cash and equivalents$347.6M$298.3M$389.5M$211.9M$923.0M
Total assets$2.27B$2.24B$2.23B$2.24B$2.75B
Total liabilities$343.4M$310.0M$346.8M$367.6M$352.4M
Shareholders' equity$1.92B$1.93B$1.88B$1.88B$2.40B

As CRISPR Therapeutics AG tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 12, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in CRSP's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 2, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeOct 19, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 5.03, 5.07, 9.01Officer / director change · Bylaw amendment · Shareholder voteJun 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
    EDGAR ↗

About CRISPR Therapeutics AG

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersZUG
IncorporatedV8
Former namesCRISPR Therapeutics AG